Coadministration of pexidartinib (a CYP3A4 inducer) with sensitive CYP3A substrates may well cause serious therapeutic failures. If concomitant use is unavoidable, improve the CYP3A substrate dosage in accordance with approved solution labeling.Coadministration with CYP3A4 substrates, particularly All those with a narrow therapeutic index, may lead… Read More